Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression

por Katz, Eva G., Hough, David, Doherty, Teodora, Lane, Rosanne, Singh, Jaskaran, Levitan, Bennett
Publicado 2020

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program

por Doherty, Teodora, Wajs, Ewa, Melkote, Rama, Miller, Janice, Singh, Jaskaran B., Weber, Michael A.
Publicado 2020

Suicide‐specific mortality among patients with treatment‐resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major d...

por Kern, David M., Canuso, Carla M., Daly, Ella, Johnson, Jonathan C., Fu, Dong Jing, Doherty, Teodora, Blauer‐Peterson, Cori, Cepeda, M. Soledad
Publicado 2023

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study

por Zaki, Naim, Chen, Li (Nancy), Lane, Rosanne, Doherty, Teodora, Drevets, Wayne C., Morrison, Randall L., Sanacora, Gerard, Wilkinson, Samuel T., Popova, Vanina, Fu, Dong-Jing
Publicado 2023